Prescription drug · ANDA
Ramelteon NDC 72189-153
Ramelteon 8 mg/1 · Tablet · Oral · DIRECT RX
NDC codes
FDA NDC Directory| Package NDC | 11-digit (billing) | Package | Copy |
|---|---|---|---|
| 72189-153-30 | 72189015330 | 30 TABLET in 1 BOTTLE (72189-153-30)Marketed from Nov 3, 2020 |
How the 11-digit form is made: The product segment has 3 digits, so one leading zero is added to it (5-3-2 → 5-4-2). Formatting the NDC does not by itself make it billable — the product, package and quantity must match what was dispensed or administered, and payer rules apply. Conversion rules
Product information
- Brand name (proprietary)
- Ramelteon
- Generic name (nonproprietary)
- ramelteon
- Active ingredients
- Ramelteon — 8 mg/1
- Dosage form
- Tablet
- Route
- Oral
- Labeler
- DIRECT RX
- Product type
- Prescription drug
- Marketing category
- ANDA — Abbreviated New Drug Application (generic)Application ANDA 211567
- Marketing start
- Listing expires
- Other FDA classes
- Melatonin Receptor Agonists (Mechanism)
- Identifiers
- Product ID 72189-153_2be9051e-225a-8882-e063-6294a90a543aSPL ID 2be9051e-225a-8882-e063-6294a90a543aSPL set ID b336438f-7951-d3b7-e053-2995a90a4d69RxCUI 577348UNII 901AS54I69
- Pharmacologic class
- Melatonin Receptor Agonist
Billing references
What Med-Code can say about coding this product, and where each statement comes from. Nothing here is inferred from the name alone.
- HCPCS codeNo match
No HCPCS code in Med-Code's directory. Oral products like this are usually dispensed by a pharmacy and billed by NDC.
- NDC on a medical claim
N472189015330followed by a unit qualifier and the quantityPackage 72189-0153-30. Unit qualifiers: F2 (international unit), GR (gram), ME (milligram), ML (milliliter), UN (unit (each)). The qualifier and quantity depend on what was given. About the N4 qualifier
Product label
Current FDA label (SPL), effective .
Indications (excerpt from the label)
Ramelteon tablets are indicated for the treatment of insomnia characterized by difficulty with sleep onset. The clinical trials performed in support of efficacy were up to six months in duration. The final formal assessments of sleep latency were performed after two days of treatment during the crossover study (elderly only), at five weeks in the six week studies (adults and elderly), and at the end of the six month study (adults and elderly) [see Clinical Studies (14)].
Excerpt only. Read the full label for complete information.
Other NDCs under ANDA 211567
Products listed under the same FDA application: other strengths and forms, and repackagers who relabel the same product.
| Product | Strength | Form · route | Labeler | Product NDC |
|---|---|---|---|---|
| Ramelteon | Ramelteon 8 mg/1 | TabletOral | Asclemed USA, Inc. | 76420-628 |
| Ramelteon | Ramelteon 8 mg/1 | TabletOral | Major Pharmaceuticals | 0904-7494 |
| Ramelteon | Ramelteon 8 mg/1 | TabletOral | Bryant Ranch Prepack | 71335-1853 |
| Ramelteon | Ramelteon 8 mg/1 | TabletOral | Zydus Pharmaceuticals USA Inc. | 70710-1344 |
| Ramelteon | Ramelteon 8 mg/1 | TabletOral | American Health Packaging | 60687-692 |
| Ramelteon | Ramelteon 8 mg/1 | TabletOral | Zydus Lifesciences Limited | 70771-1495 |